|
gptkbp:instanceOf
|
gptkb:public_company
|
|
gptkbp:CEO
|
gptkb:Kevin_Sayer
|
|
gptkbp:founded
|
1999
|
|
gptkbp:founder
|
gptkb:Scott_Glenn
|
|
gptkbp:headquartersLocation
|
gptkb:San_Diego,_California,_United_States
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Dexcom, Inc.
|
|
gptkbp:industry
|
medical devices
|
|
gptkbp:ISIN
|
US2521311074
|
|
gptkbp:keyPerson
|
gptkb:Michael_Brown
gptkb:Eric_Topol
gptkb:Kevin_Sayer
gptkb:Barbara_W._Bodem
gptkb:Bridgette_P._Heller
gptkb:Chad_Patterson
gptkb:Karen_Dahut
gptkb:Mark_G._Foletta
gptkb:Nicholas_Augustinos
gptkb:Quentin_Blackford
gptkb:Richard_A._Collins
gptkb:Steven_R._Altman
Donald A. Lucas
Jacob Leach
James S. Scapa
Jay S. Skyler
Matthew Dolan
R. Andrew Eckert
Richard Doubleday
Steven R. Pacelli
Terrance H. Gregg
|
|
gptkbp:marketCap
|
over $40 billion (2023)
|
|
gptkbp:netIncome
|
$341 million (2022)
|
|
gptkbp:notableProduct
|
gptkb:Dexcom_G6
gptkb:Dexcom_G7
|
|
gptkbp:numberOfEmployees
|
over 7,000
|
|
gptkbp:product
|
continuous glucose monitoring systems
|
|
gptkbp:revenue
|
$2.91 billion (2022)
|
|
gptkbp:servesArea
|
worldwide
|
|
gptkbp:specializesIn
|
diabetes management
|
|
gptkbp:stockSymbol
|
gptkb:DXCM
|
|
gptkbp:tradedOn
|
gptkb:NASDAQ
|
|
gptkbp:type
|
public
|
|
gptkbp:website
|
https://www.dexcom.com/
|
|
gptkbp:bfsParent
|
gptkb:NASDAQ:DXCM
gptkb:DXCM
gptkb:Dexcom_G7
|
|
gptkbp:bfsLayer
|
7
|